1 unchanged sentence
Management ’ s Evaluation of our Disclosure Controls and Procedures
−Removed: Under the supervision of and with the participation of our management, including our principal executive officer and our principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2023, the end of the period covered by this Form 10-K.
+Added: Under the supervision of and with the participation of our management, including our principal executive officer, our principal financial officer and our principal accounting officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2024, the end of the period covered by this Form 10-K.
The term “disclosure controls and procedures,” as set forth in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms promulgated by the SEC.
63 unchanged sentences
(incorporated by reference to Exhibit 10.16 to the Annual Report on Form 10-K filed with the SEC on March 5, 2021)
+Added: Lease Agreement, effective as of September 27, 2024, by and between ICE BOX, LLC and Compass Therapeutics, Inc.
+Added: (incorporated by reference to Exhibit 10.13 to the Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024)
Employment Agreement between Compass Therapeutics, Inc.
and Thomas J.
−Removed: Schuetz, M.D., Ph.D., dated January 8, 2024
+Added: Schuetz, M.D., Ph.D., dated January 8, 2024 (incorporated by reference to Exhibit 10.10 to the Annual Report on Form 10-K filed with the SEC on March 21, 2024 )
Employment Agreement between Compass Therapeutics, Inc.
−Removed: and Vered Bisker-Leib, Ph.D., M.B.A., dated January 8, 2024
+Added: and Barry Shin, dated December 9, 2024 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on December 10, 2024)
+Added: Separation Agreement, dated May 28, 2024, by and between Compass Therapeutics, Inc.
+Added: and Vered Bisker-Leib, PhD (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on May 28, 2024)
+Added: Consulting Agreement, dated May 28, 2024, by and between Compass Therapeutics, Inc.
+Added: and Vered Bisker-Leib, PhD (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed with the SEC on May 28, 2024)
Research and Development Collaboration and License Agreement, dated November 30, 2018, between Trigr Therapeutics, Inc.
1 unchanged sentence
(incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed with the SEC on August 16, 2021)
+Added: Insider Trading Compliance Policy
Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Current Report on Form 8-K filed with the SEC on June 23, 2020)
3 unchanged sentences
Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C.
+Added: Certification of Principal Executive Officer Pursuant to 18 U.S.C.
Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: Registrant’s Compensation Clawback Policy
+Added: Certification of Principal Financial Officer Pursuant to 18 U.S.C.
+Added: Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
+Added: Registrant’ s Compensation Clawback Policy (incorporated by reference to Exhibit 97.1 to the Annual Report on Form 10-K filed with the SEC on March 21, 2024)
Inline XBRL Instance Document
13 unchanged sentences
Compass Therapeutics, Inc.
−Removed: March 21, 2024
−Removed: /s/ Vered Bisker-Leib
−Removed: Vered Bisker-Leib
+Added: February 27, 2025
+Added: /s/ Thomas Schuetz
+Added: Thomas Schuetz
Chief Executive Officer
POWER OF ATTORNEY AND SIGNATURES
−Removed: Each person whose individual signature appears below hereby authorizes and appoints Vered Bisker-Leib, Ph.D.
−Removed: Gordon, Ph.D., and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue thereof.
+Added: Each person whose individual signature appears below hereby authorizes and appoints Thomas J.
+Added: Schuetz, Barry Shin and Carl L.
+Added: Gordon, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his or her substitute or substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
−Removed: /s/ Vered Bisker-Leib
−Removed: Chief Executive Officer and Director (Principal Executive Officer and Principal Financial and Accounting Officer)
−Removed: March 21, 2024
−Removed: Vered Bisker-Leib
−Removed: Chair of the Board
−Removed: March 21, 2024
/s/ Thomas J.
−Removed: Vice Chair of the Board
−Removed: March 21, 2024
+Added: Chief Executive Officer and Vice Chair of the Board (Principal Executive Officer)
+Added: February 27, 2025
+Added: /s/ Barry Shin
+Added: Chief Financial Officer (Principal Financial Officer)
+Added: February 27, 2025
+Added: /s/ Neil Lerner
+Added: Chief Accounting Officer (Principal Accounting Officer)
+Added: February 27, 2025
+Added: Chair of the Board
+Added: February 27, 2025
/s/ Phil Ferneau
−Removed: March 21, 2024
+Added: February 27, 2025
/s/ Mary Ann Gray
−Removed: March 21, 2024
+Added: February 27, 2025
Mary Ann Gray
/s/ Ellen Chiniara
−Removed: March 21, 2024
+Added: February 27, 2025
Ellen Chiniara
/s/ James Boylan
−Removed: March 21, 2024
+Added: February 27, 2025
/s/ Richard Lindahl
−Removed: March 21, 2024
+Added: February 27, 2025
Richard Lindahl
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.